{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:07Z","timestamp":1786119427924,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1097\/adm.0b013e3181add3de","type":"journal-article","created":{"date-parts":[[2010,2,19]],"date-time":"2010-02-19T03:17:05Z","timestamp":1266549425000},"page":"20-26","source":"Crossref","is-referenced-by-count":59,"title":["Successful Integration of Hepatitis C Evaluation and Treatment Services With Methadone Maintenance"],"prefix":"10.1097","volume":"4","author":[{"given":"Kenneth A.","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia H.","family":"Arnsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H.","family":"Litwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210126","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"R2-3-20210126","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1086\/499960","article-title":"Injection drug users: The overlooked core of the hepatitis C epidemic.","volume":"42","author":"Edlin","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R3-3-20210126","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jama.285.8.1003","article-title":"Former addicts face barriers to treatment for HCV.","volume":"285","author":"Stephenson","year":"2001","journal-title":"JAMA"},{"key":"R4-3-20210126","first-page":"1","article-title":"National Institutes of Health Consensus Development Conference Statement, Management of Hepatitis C.","year":"2002"},{"key":"R5-3-20210126","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/jhep.2001.25882","article-title":"Treatment of hepatitis C infection in injection drug users.","volume":"34","author":"Backmund","year":"2001","journal-title":"Hepatology"},{"key":"R6-3-20210126","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0376-8716(02)00010-8","article-title":"Treating hepatitis C in methadone maintenance patients: An interim analysis.","volume":"67","author":"Sylvestre","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"R7-3-20210126","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000049487","article-title":"Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up.","volume":"8","author":"Dalgard","year":"2002","journal-title":"Eur Addict Res"},{"key":"R8-3-20210126","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/S0002-9270(03)00708-1","article-title":"Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse.","volume":"98","author":"Van Thiel","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R9-3-20210126","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0399-8320(04)95008-7","article-title":"Management of hepatitis C inactive drug users: Experience of an addiction care hepatology unit.","volume":"28","author":"Cournot","year":"2004","journal-title":"Gastroenterol Clin Biol"},{"key":"R10-3-20210126","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.20279","article-title":"A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance.","volume":"40","author":"Mauss","year":"2004","journal-title":"Hepatology"},{"key":"R11-3-20210126","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s15010-005-4043-2","article-title":"Interferon alpha-2a plus ribavirin 1,000\/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: An open-label randomized multicenter trial.","volume":"33","author":"Huber","year":"2005","journal-title":"Infection"},{"key":"R12-3-20210126","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.1086\/427447","article-title":"Treating hepatitis C virus infection in active substance users.","volume":"40","author":"Sylvestre","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R13-3-20210126","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00042737-200602000-00008","article-title":"Similar compliance and effect of treatment in chronic hepatitis C resulting from intervenous drug use in comparison with other infection causes.","volume":"18","author":"Robaeys","year":"2006","journal-title":"Eur J Gatroenterol Hepatol"},{"key":"R14-3-20210126","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jsat.2004.12.004","article-title":"Knowledge of and interest in hepatitis C treatment at a methadone clinic.","volume":"28","author":"Walley","year":"2005","journal-title":"J Subst Abuse Treat"},{"key":"R15-3-20210126","doi-asserted-by":"crossref","first-page":"288","DOI":"10.7326\/0003-4819-136-4-200202190-00008","article-title":"Surprisingly small effect of antiviral treatment in patients with hepatitis C.","volume":"136","author":"Falck-Ytter","year":"2002","journal-title":"Ann Intern Med"},{"key":"R16-3-20210126","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/01.qai.0000131932.21612.49","article-title":"Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection.","volume":"37","author":"Fishbein","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R17-3-20210126","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11524-007-9180-8","article-title":"Offers of hepatitis C care do not lead to treatment.","volume":"84","author":"Schackman","year":"2007","journal-title":"J Urban Health"},{"key":"R18-3-20210126","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-111-9-761","article-title":"Primary care for patients with human immunodeficiency virus (HIV) infection in a methadone maintenance treatment program.","volume":"111","author":"Selwyn","year":"1989","journal-title":"Ann Intern Med"},{"key":"R19-3-20210126","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1300\/J069v15n01_07","article-title":"Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program.","volume":"15","author":"Gourevitch","year":"1996","journal-title":"J Addict Dis"},{"key":"R20-3-20210126","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jsat.2006.12.001","article-title":"Hepatitis C management by addiction medicine physicians: Results from a national survey.","volume":"33","author":"Litwin","year":"2007","journal-title":"J Subst Abuse Treat"},{"key":"R21-3-20210126","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1086\/427450","article-title":"Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities.","volume":"40","author":"Litwin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R22-3-20210126","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"AASLD Practice Guideline: Diagnosis, management and treatment of chronic hepatitis C.","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"R23-3-20210126","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis.","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"R24-3-20210126","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon lafa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial.","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R25-3-20210126","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R26-3-20210126","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"R27-3-20210126","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"R28-3-20210126","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1365-2893.2005.00682.x","article-title":"Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2\/3, and this is not explained by more frequent dose reductions of interferon and ribavirin.","volume":"13","author":"Br\u00e4u","year":"2006","journal-title":"J Viral Hepat"},{"key":"R29-3-20210126","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMoa0805062","article-title":"Peginterferon alfa-2a and ribavirin in Latino and non-Latino Whites with hepatitis C.","volume":"360","author":"Rodriguez-Torres","year":"2009","journal-title":"New Engl J Med"}],"container-title":["Journal of Addiction Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01271255-201003000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:13:56Z","timestamp":1786040036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01271255-201003000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/adm.0b013e3181add3de","relation":{},"ISSN":["1932-0620"],"issn-type":[{"value":"1932-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}